Transurethral resection of the prostate (TURP) has remained a staple of urological surgery for decades due to its minimal invasiveness, low complication rates, and high success in relieving symptoms of BPH. It is primarily indicated for patients whose enlarged prostate causes significant bladder outlet obstruction that fails to respond to conservative treatments. Moreover, it is used in cases where complications such as recurrent urinary tract infections, bladder stones, or kidney damage are present due to chronic urinary retention. While newer techniques such as laser-based procedures (e.g., holmium laser enucleation of the prostate or HoLEP) have gained popularity, TURP remains a widely used procedure because of its established track record and reliable outcomes, particularly in cases of moderate to large prostate enlargement.
The minimally invasive nature of TURP allows patients to avoid open surgery, reducing recovery times and minimizing the risks associated with larger surgical procedures. However, as with any surgical procedure, TURP is not without potential complications, including bleeding, infection, and the risk of developing TURP syndrome—a condition caused by excessive absorption of irrigation fluids during the procedure, leading to hyponatremia. Despite these risks, TURP continues to be one of the most effective procedures for treating BPH, with most patients experiencing significant improvements in urinary flow and overall quality of life following the surgery.
